Literature DB >> 24462168

Endoscopically identified well-differentiated rectal carcinoid tumors: impact of tumor size on the natural history and outcomes.

Ferga C Gleeson1, Michael J Levy1, Eric J Dozois2, David W Larson2, Louis Michel Wong Kee Song1, Lisa A Boardman1.   

Abstract

BACKGROUND: There is a paucity of data pertaining to the natural history and outcomes of patients with well-differentiated rectal carcinoids.
OBJECTIVE: To correlate endoscopic size with the natural history and outcome.
DESIGN: Retrospective study.
SETTING: Single tertiary referral center. PATIENTS: Eighty-seven patients with endoscopically identified well-differentiated rectal carcinoid tumors. INTERVENTION: Colonoscopy. MAIN OUTCOME MEASUREMENTS: Prevalence of metastasis at diagnosis, disease progression, and survival.
RESULTS: Metastasis was present at diagnosis in 3%, 66%, and 73% of tumors measuring ≤10 mm, 11 to 19 mm, and ≥20 mm, respectively. Metastasis was predicted with 100% sensitivity and 87% specificity using an endoscopic lesion size ≥9 mm. In patients without identified metastasis, 64% were identified during screening colonoscopy. Within this select cohort, subsequent metastasis was discovered only at distant extra pelvic sites, in 1.6%, 50%, and 100% of patients with tumors initially measuring ≤10 mm, 11 to 19 mm, and ≥20 mm, respectively. The carcinoid related 5- and 10-year survival rates for locally confined disease were 96%. The corresponding survival rates for local and advanced metastatic disease were 60% and 35%, respectively. LIMITATIONS: Subjective estimation of tumor size, mitotic index or Ki-67 labeling index not reported, and lack of formal and standardized baseline staging algorithm and surveillance program.
CONCLUSIONS: The clinical behavior of 11- to 19-mm tumors appears to mimic that of larger (>20 mm) lesions with respect to the presence of metastasis at diagnosis and disease progression. Therefore, if local therapy is contemplated, we propose to make a distinction between ≤10-mm and 11- to 19-mm tumors, favoring an aggressive staging and management protocol for 11- to 19-mm carcinoid tumors.
Copyright © 2014 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24462168     DOI: 10.1016/j.gie.2013.11.031

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  20 in total

1.  Analysis of the factors affecting lymph node metastasis and the prognosis of rectal neuroendocrine tumors.

Authors:  Peng Li; Fan Wu; Hong Zhao; Lizhou Dou; Yang Wang; Chunguang Guo; Guiqi Wang; Dongbing Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  The Ki-67 labeling index and lymphatic/venous permeation predict the metastatic potential of rectal neuroendocrine tumors.

Authors:  Shinya Sugimoto; Kinichi Hotta; Tadakazu Shimoda; Kenichiro Imai; Yuichiro Yamaguchi; Takashi Nakajima; Takuma Oishi; Keita Mori; Kohei Takizawa; Naomi Kakushima; Masaki Tanaka; Noboru Kawata; Hiroyuki Matsubayashi; Hiroyuki Ono
Journal:  Surg Endosc       Date:  2015-12-30       Impact factor: 4.584

3.  Characteristics and long-term prognosis of patients with rectal neuroendocrine tumors.

Authors:  Yihebali Chi; Feng Du; Hong Zhao; Jin-Wan Wang; Jian-Qiang Cai
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

Review 4.  Hindgut Neuroendocrine Neoplasia.

Authors:  James D Smith; Govind Nandakumar
Journal:  Indian J Surg Oncol       Date:  2015-10-26

5.  Advantage of endoscopic mucosal resection with a cap for rectal neuroendocrine tumors.

Authors:  Su Bum Park; Hyung Wook Kim; Dae Hwan Kang; Cheol Woong Choi; Su Jin Kim; Hyeong Seok Nam
Journal:  World J Gastroenterol       Date:  2015-08-21       Impact factor: 5.742

6.  Long-Term Clinical Outcomes of Rectal Neuroendocrine Tumors According to the Pathologic Status After Initial Endoscopic Resection: A KASID Multicenter Study.

Authors:  Chang Mo Moon; Kyu Chan Huh; Sung-Ae Jung; Dong Il Park; Won Hee Kim; Hye Mi Jung; Seong-Joon Koh; Jin-Oh Kim; Yunho Jung; Kyeong Ok Kim; Jong Wook Kim; Dong-Hoon Yang; Jeong Eun Shin; Sung Jae Shin; Eun Soo Kim; Young-Eun Joo
Journal:  Am J Gastroenterol       Date:  2016-07-05       Impact factor: 10.864

Review 7.  Small Bowel and Colorectal Carcinoids.

Authors:  Raphael M Byrne; Rodney F Pommier
Journal:  Clin Colon Rectal Surg       Date:  2018-09-04

8.  Risk Factors for Development of Rectal Neuroendocrine Tumors Longer Than 9 mm: Retrospective Cohort.

Authors:  Juliana Silveira Lima de Castro; Evandra Cristina Vieira da Rocha; Vanessa Assis do Vale; Paula Mendonça; Oswaldo Wiliam Marques; Eloy Taglieri; Francisco Susumu Correa Koyama; Celso Augusto Milani Cardoso Filho; Wilson Toshihiko Nakagawa
Journal:  Turk J Gastroenterol       Date:  2021-08       Impact factor: 1.852

9.  Hindgut neuroendocrine neoplasms - characteristics and prognosis.

Authors:  Paweł Gut; Joanna Waligórska-Stachura; Agata Czarnywojtek; Nadia Sawicka-Gutaj; Maciej Bączyk; Katarzyna Ziemnicka; Kosma Woliński; Ariadna Zybek; Jakub Fischbach; Marek Ruchała
Journal:  Arch Med Sci       Date:  2017-01-06       Impact factor: 3.318

10.  Factors associated with worse outcomes for colorectal neuroendocrine tumors in radical versus local resections.

Authors:  Osayande Osagiede; Elizabeth Habermann; Courtney Day; Emmanuel Gabriel; Amit Merchea; Riccardo Lemini; Iktej S Jabbal; Dorin T Colibaseanu
Journal:  J Gastrointest Oncol       Date:  2020-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.